

1st LINE Therapeutic

Unresectable

UCI 01-61

A Humanitarian device exemption use protocol of TheraSphere for treatment of Unresectable Hepatocellular Carcinoma (Imagawa)

UCI 15-80

Phase III Comparing Pexa-Vec Followed by Sorafenib vs. Sorafenib Pts w/ HCC w/o Prior Systemic Therapy (Abi-Jaoudeh)

EAY131 (MATCH)

Molecular Analysis for Therapy Choice (Seery)

UCI 15-81

Phase 1 Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Hepatocellular Carcinoma (Abi-Jaoudeh)

UCI 16-40

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects with Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma (Imagawa)

LIVER CANCER

RootFolder=%2Fsites%2Fcancer%

Correlative

UCI 03-03 Immunologic Factors Affecting Outcomes in Patients with Liver Cancer (Imagawa)

UCI 16-29** Dynamic Contrast Enhanced Magnetic Resonance Imaging as a Biomarker to Predict Response to Liver Tumor Embolization (Lam)

2nd LINE Therapeutic

UCI 16-94

Phase IIA Single Arm Study of Treatment of Patients with Advanced Liver Cancer with a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD1 monoclonal antibody (Abi-Jaoudeh)

Unresectable or Metastatic

UCI 16-81**

Comparing trans-arterial chemoembolization outcome using cone beam CT vs. conventional fluoroscopy (Abi-Jaoudeh)

UCI 16-64 A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 IN Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations who Failed Previous Therapy (Seery)